1Aroa Biosurgery (ARX) –MASTRR Interim AnalysisUNLOCKING REGENERATIVE HEALING FOR EVERYBODY2| Unlocking regenerative healing for everybody.Important Notice and DisclaimerThis presentation (07 Oct 2026) has been prepared by Aroa Biosurgery Limited, New Zealand company number 1980577, ARBN 638...
Investor Presentation - MASTRR Interim Analysis
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Aroa Biosurgery
- Change in substantial holding
- Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
- Symphony Significantly Improves DFU Healing
- Invite to Investor Webinar on MASTRR Interim Analysis
- Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
Later from Aroa Biosurgery
- Invite to Investor Webinar on Symphony RCT
- Investor Presentation - Symphony RCT
- Notification of cessation of securities - ARX
- Molnlycke to Co-promote Endoform In the US
- Change in substantial shareholding for ARX
Follow Aroa Biosurgery into a list and get an email when it puts out news.
Follow Aroa Biosurgery